The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Atea Pharmaceuticals offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines the advantages of current first-line HCV therapies—single pill ...
“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...
Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results